INDIA COURT RULING AGAINST NOVARTIS IS DARK OMEN FOR BIG PHARMA $NVS $LLY $BMY $MRK $JNJ $PFE

Twitter
LinkedIn
Facebook

indian supreme second image 4-2-13

It is official: India is siding with poor cancer patients over profits for multinational drug giants.

The Supreme Court of India has rejected a plea by Swiss pharma giant Novartis that ends the seven-year legal battle to restrict Indian companies from copying blood cancer drug Glivec.  Novartis had filed a plea with the Supreme Court after the Intellectual Property Appellate Board had rejected a patent claim for Glivec.

Glivec is marketed as Gleevec in the United States.  In 2001, Time magazine called it the magic bullet for cancer patients. The drug was originally developed as Imatinib using rational drug design after Philadelphia chromosome mutation was discovered.

In India, Glivec costs about 120,000 rupees for a one month dose.  In contrast, generic copies by Indian companies cost about 8,000 rupees, or about $148 at current exchange rates.

The decision is being hailed by activists and has major implications for multinational pharmaceutical firms.  The decision opens the door for Indian companies to continue to make generics of a large number of drugs that are under patent in the developed world.

The decision is also a big setback for the ever-greening strategy employed by big pharma.  In this strategy, big pharma makes minor changes to extend patents.

Lately, American investors have shown irrational exuberance about pharmaceutical stocks.  Pharmaceutical stocks have been one of the best performing groups.

Bulls on pharmaceutical stocks cite two reasons behind their analysis…Read more at Forbes

Subscribe to 'Generate Wealth'

Free Forever

More To Explore

30 Day Free Trial

Cancel within 30 days and you owe nothing

When you take a FREE 30 day trial, you get access to powerful techniques used by billionaires and hedge funds to grow richer. You can continue to use these powerful techniques to grow richer even if you cancel your subscription. You come out ahead by subscribing no matter how you look at it.

A fortune is to be made from AI stocks.
Get the list of 18 AI stocks to grab your share of the profits — no cost to you.

A fortune is to be made from AI stocks.

Get the list of 18 AI stocks to grab your share of the profits.

AI is a $1 Trillion Market

Making A Fortune
In Artificial Intelligence

Golden Age of Artificial Intelligence